110.92
price down icon1.97%   -2.165
 
loading
前日終値:
$113.08
開ける:
$113.32
24時間の取引高:
1.52M
Relative Volume:
0.64
時価総額:
$222.45B
収益:
$53.22B
当期純損益:
$12.86B
株価収益率:
17.36
EPS:
6.39
ネットキャッシュフロー:
$14.85B
1週間 パフォーマンス:
-2.29%
1か月 パフォーマンス:
+4.72%
6か月 パフォーマンス:
+3.78%
1年 パフォーマンス:
+13.42%
1日の値動き範囲:
Value
$110.67
$113.40
1週間の範囲:
Value
$110.43
$114.88
52週間の値動き範囲:
Value
$96.06
$120.92

Novartis Ag Adr Stock (NVS) Company Profile

Name
名前
Novartis Ag Adr
Name
セクター
Healthcare (1160)
Name
電話
-
Name
住所
-
Name
職員
75,883
Name
Twitter
@novartis
Name
次回の収益日
2025-01-31
Name
最新のSEC提出書
Name
NVS's Discussions on Twitter

NVS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
110.89 222.45B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
LLY
Lilly Eli Co
775.15 737.81B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
154.40 370.90B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
186.99 340.25B 57.37B 4.20B 17.83B 2.35
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
66.29 277.97B 42.09B 14.65B 10.11B 3.2833

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-13 ダウングレード UBS Buy → Neutral
2025-02-12 開始されました Morgan Stanley Underweight
2025-02-04 アップグレード Deutsche Bank Hold → Buy
2024-12-04 ダウングレード HSBC Securities Hold → Reduce
2024-09-11 ダウングレード BofA Securities Buy → Neutral
2024-09-05 ダウングレード Goldman Buy → Neutral
2024-09-03 ダウングレード Jefferies Buy → Hold
2024-07-19 ダウングレード Deutsche Bank Buy → Hold
2024-05-30 開始されました Goldman Buy
2024-02-23 開始されました BMO Capital Markets Market Perform
2024-01-23 開始されました Morgan Stanley Equal-Weight
2024-01-16 再開されました UBS Buy
2023-12-18 ダウングレード HSBC Securities Buy → Hold
2023-09-25 アップグレード Morgan Stanley Underweight → Equal-Weight
2023-07-14 開始されました HSBC Securities Buy
2023-04-26 アップグレード Deutsche Bank Hold → Buy
2023-03-27 アップグレード Deutsche Bank Sell → Hold
2023-01-26 ダウングレード Citigroup Buy → Neutral
2022-12-05 アップグレード Stifel Hold → Buy
2022-09-15 ダウングレード Credit Suisse Neutral → Underperform
2022-09-14 ダウングレード Berenberg Buy → Hold
2022-05-09 ダウングレード Wolfe Research Outperform → Peer Perform
2022-01-10 再開されました Citigroup Buy
2021-12-14 ダウングレード Redburn Buy → Neutral
2021-12-06 ダウングレード Exane BNP Paribas Outperform → Neutral
2021-12-03 ダウングレード Bryan Garnier Buy → Neutral
2021-09-20 ダウングレード Deutsche Bank Hold → Sell
2021-03-22 開始されました Bernstein Mkt Perform
2021-03-10 ダウングレード Argus Buy → Hold
2021-02-01 ダウングレード Cowen Outperform → Market Perform
2021-01-15 開始されました Deutsche Bank Buy
2020-09-29 開始されました Berenberg Buy
2020-09-10 アップグレード UBS Neutral → Buy
2020-09-01 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-06-15 アップグレード Citigroup Neutral → Buy
2020-03-10 アップグレード Morgan Stanley Underweight → Equal-Weight
2020-02-25 ダウングレード Guggenheim Buy → Neutral
2019-04-25 アップグレード Guggenheim Neutral → Buy
2019-04-25 アップグレード Liberum Hold → Buy
2019-04-10 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-01-02 ダウングレード JP Morgan Neutral → Underweight
2018-12-11 再開されました Jefferies Buy
2018-10-09 開始されました Guggenheim Neutral
2018-09-10 アップグレード BofA/Merrill Underperform → Buy
2018-05-29 ダウングレード HSBC Securities Buy → Hold
2018-05-25 アップグレード Credit Suisse Underperform → Neutral
2018-01-25 繰り返されました Leerink Partners Outperform
2017-12-06 ダウングレード BofA/Merrill Neutral → Underperform
2017-07-26 アップグレード Morgan Stanley Underweight → Overweight
2017-07-05 ダウングレード Credit Suisse Neutral → Underperform
2017-03-09 開始されました Liberum Buy
すべてを表示

Novartis Ag Adr (NVS) 最新ニュース

pulisher
May 02, 2025

NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

Liver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research® - GlobeNewswire Inc.

May 02, 2025
pulisher
Apr 29, 2025

Novartis Earnings: Strong First-Quarter Supports Increased Full-Year Guidance - Morningstar

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis ADR earnings beat by $0.20, revenue topped estimates - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis Beats On Q1 Earnings And Sales, Raises Guidance, Stock Up - Barchart.com

Apr 29, 2025
pulisher
Apr 22, 2025

Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs - The Globe and Mail

Apr 22, 2025
pulisher
Apr 21, 2025

Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? - Yahoo Finance

Apr 21, 2025
pulisher
Apr 11, 2025

Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com

Apr 11, 2025
pulisher
Apr 11, 2025

Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Newmont - WSJ

Apr 11, 2025
pulisher
Apr 04, 2025

Pharma Stock Roundup: FDA Nod To SNY, AZN & NVS, JNJ Talc Suits Failure - Barchart.com

Apr 04, 2025
pulisher
Apr 03, 2025

FDA Grants Accelerated Approval To NVS Kidney Disease Drug - Barchart.com

Apr 03, 2025
pulisher
Apr 03, 2025

Quantum Corp’s Banking’s 100-Day Moving Average at 21.57: Will the Stock Break Through? - investchronicle.com

Apr 03, 2025
pulisher
Mar 26, 2025

No room on the ARK? - Morningstar

Mar 26, 2025
pulisher
Mar 25, 2025

5 Large Drug Stocks To Watch As Industry Recovers - Barchart

Mar 25, 2025
pulisher
Mar 21, 2025

FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart

Mar 21, 2025
pulisher
Mar 19, 2025

Novartis scraps use of diverse panels for hires in US - Reuters

Mar 19, 2025
pulisher
Mar 14, 2025

Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart

Mar 14, 2025
pulisher
Mar 13, 2025

Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.

Mar 13, 2025
pulisher
Mar 12, 2025

Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.

Mar 12, 2025
pulisher
Mar 07, 2025

Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart

Mar 07, 2025
pulisher
Mar 07, 2025

Giovanni Caforio, M.D. - Novartis

Mar 07, 2025
pulisher
Mar 05, 2025

Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily

Mar 05, 2025
pulisher
Mar 04, 2025

META_TITLE_QUOTE - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily

Mar 04, 2025
pulisher
Mar 03, 2025

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance

Mar 03, 2025
pulisher
Feb 26, 2025

AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com

Feb 26, 2025
pulisher
Feb 25, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Feb 25, 2025
pulisher
Feb 21, 2025

NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com

Feb 21, 2025
pulisher
Feb 18, 2025

NVS Quantitative Stock Analysis - Nasdaq

Feb 18, 2025
pulisher
Feb 16, 2025

Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha

Feb 16, 2025
pulisher
Feb 13, 2025

Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Feb 13, 2025
pulisher
Feb 13, 2025

Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH - Barchart

Feb 13, 2025

Novartis Ag Adr (NVS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general MRK
$78.59
price down icon 5.20%
drug_manufacturers_general NVO
$66.20
price down icon 4.24%
$270.14
price down icon 3.63%
$97.90
price down icon 4.88%
drug_manufacturers_general PFE
$22.96
price down icon 3.83%
大文字化:     |  ボリューム (24 時間):